Phase I Combination w/ Epirubicin

A Phase I Study of Ixabepilone in Combination With Epirubicin in Patients With Metastatic Breast Cancer

Tumor response information was obtained for all participants who received at least 2 cycles of study drug, underwent requisite baseline and on-treatment disease assessments and had at least one post-treatment assessment. Tumor response assessment in evaluable participants was done according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Inclusion Criteria:

• Women ≥18 years
• Histologically or cytologically confirmed diagnosis of metastatic breast cancer
• Measurable or nonmeasurable disease defined by Response Evaluation Criteria In Solid Tumors (RECIST)

Exclusion Criteria:

• Number of prior chemotherapy lines of treatment in the metastatic setting ≥2